home / stock / nuvl / nuvl quote
Last: | $79.945 |
---|---|
Change Percent: | 2.63% |
Open: | $78.46 |
Close: | $77.90 |
High: | $80.0496 |
Low: | $76.615 |
Volume: | 68,911 |
Last Trade Date Time: | 07/31/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$79.945 | $78.46 | $77.9 | $80.0496 | $76.615 | 68,911 | 07-31-2024 |
$77.9 | $79.99 | $77.9 | $81.07 | $77.29 | 166,428 | 07-30-2024 |
$79.12 | $81.68 | $79.12 | $81.78 | $78.45 | 315,606 | 07-29-2024 |
$81.61 | $81.42 | $81.61 | $83.165 | $81.23 | 160,942 | 07-26-2024 |
$79.95 | $80.65 | $79.95 | $82.17 | $79.32 | 263,412 | 07-25-2024 |
$80.3 | $81.61 | $80.3 | $83.54 | $80.02 | 139,044 | 07-24-2024 |
$82.51 | $81.11 | $82.51 | $83.23 | $81.11 | 178,898 | 07-23-2024 |
$81.14 | $79.37 | $81.14 | $81.21 | $78.77 | 235,046 | 07-22-2024 |
$78.96 | $80.33 | $78.96 | $80.515 | $77.53 | 234,370 | 07-19-2024 |
$79.83 | $80.66 | $79.83 | $82.01 | $79.02 | 229,712 | 07-18-2024 |
$80.5 | $82.38 | $80.5 | $83.885 | $79.15 | 921,185 | 07-17-2024 |
$84.01 | $82.82 | $84.01 | $84.75 | $81.59 | 669,472 | 07-16-2024 |
$81.45 | $78.8 | $81.45 | $82.09 | $78.05 | 594,311 | 07-15-2024 |
$78.65 | $78.91 | $78.65 | $80.73 | $77.945 | 257,560 | 07-12-2024 |
$77.99 | $75.91 | $77.99 | $79.78 | $75.23 | 405,515 | 07-11-2024 |
$74.52 | $75.12 | $74.52 | $77.19 | $73.87 | 251,806 | 07-10-2024 |
$73.63 | $72.17 | $73.63 | $73.775 | $72.17 | 252,066 | 07-09-2024 |
$72.33 | $73.92 | $72.33 | $74.6 | $71.577 | 356,600 | 07-08-2024 |
$72.87 | $71.42 | $72.87 | $73.2696 | $70.52 | 140,640 | 07-05-2024 |
$72.05 | $72.67 | $72.05 | $73.54 | $71.305 | 205,183 | 07-04-2024 |
News, Short Squeeze, Breakout and More Instantly...
Nuvalent Announces First Patient Dosed in HEROEX-1 Phase 1a/1b Clinical Trial of NVL-330, its Novel HER2-selective Inhibitor PR Newswire CAMBRIDGE, Mass. , July 22, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company foc...
Nuvalent to Present Updated Data for ROS1-Selective Inhibitor, Zidesamtinib, and ALK-Selective Inhibitor, NVL-655, at the ESMO Congress 2024 PR Newswire CAMBRIDGE, Mass. , July 16, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharma...
Nuvalent Announces Promotion of Henry Pelish, Ph.D. to Chief Scientific Officer PR Newswire CAMBRIDGE, Mass. , July 11, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely target...